Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Operating Income (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Operating Income readings, the most recent being -$5885.0 for Q3 2025.

  • On a quarterly basis, Operating Income rose 71.93% to -$5885.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $55942.0, a 158.21% increase, with the full-year FY2024 number at -$27597.0, down 11.97% from a year prior.
  • Operating Income hit -$5885.0 in Q3 2025 for Goldenwell Biotech, down from -$3120.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $72165.0 in Q4 2024 to a low of -$920332.0 in Q4 2022.
  • Median Operating Income over the past 5 years was -$20799.0 (2023), compared with a mean of -$60250.9.
  • Biggest five-year swings in Operating Income: skyrocketed 2086.05% in 2021 and later crashed 13946.58% in 2022.
  • Goldenwell Biotech's Operating Income stood at -$6552.0 in 2021, then crashed by 13946.58% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then soared by 446.96% to $72165.0 in 2024, then crashed by 108.15% to -$5885.0 in 2025.
  • The last three reported values for Operating Income were -$5885.0 (Q3 2025), -$3120.0 (Q2 2025), and -$7218.0 (Q1 2025) per Business Quant data.